Global Antiviral Combination Therapies Market reached USD 40.4 billion in 2019

Global Antiviral Combination Therapies Market Size study, by Drug Combination (NRTI/NNRTI, Integrase Inhibitor/NRTI, NRTI, NRTI/Protease Inhibitor, Others) by Type (Branded, Generic) by Indication (HIV, Hepatitis, Others) by Route of Administration (Oral, Intravenous) and Regional Forecasts 2020-2027
Product Code:  HALMD_37896278
Chapter 1.	Executive Summary 
1.1.	Market Snapshot
1.2.	Global & Segmental Market Estimates & Forecasts, 2018-2027 (USD Billion)
1.2.1.	Antiviral Combination Therapies Market, by Region, 2018-2027 (USD Billion)
1.2.2.	Antiviral Combination Therapies Market, by Drug Combination 2018-2027 (USD Billion)
1.2.3.	Antiviral Combination Therapies Market, by Type 2018-2027 (USD Billion)
1.2.4.	Antiviral Combination Therapies Market, by Indication 2018-2027 (USD Billion)
1.2.5.	Antiviral Combination Therapies Market, by Route of Administration 2018-2027 (USD Billion)
1.2.6.	Antiviral Combination Therapies Market, by Distribution Channel, 2018-2027 (USD Billion)
1.3.	Key Trends
1.4.	Estimation Methodology
1.5.	Research Assumption
Chapter 2.	Global Antiviral Combination Therapies Market Definition and Scope 
2.1.	Objective of the Study
2.2.	Market Definition & Scope
2.2.1.	Scope of the Study
2.2.2.	Industry Evolution
2.3.	Years Considered for the Study
2.4.	Currency Conversion Rates
Chapter 3.	Global Antiviral Combination Therapies Market Dynamics	
3.1.	Antiviral Combination Therapies Market Impact Analysis (2018-2027)
3.1.1.	Market Drivers
3.1.2.	Market Challenges
3.1.3.	Market Opportunities
Chapter 4.	Global Antiviral Combination Therapies Market Industry Analysis
4.1.	Porter’s 5 Force Model
4.1.1.	Bargaining Power of Suppliers
4.1.2.	Bargaining Power of Buyers
4.1.3.	Threat of New Entrants
4.1.4.	Threat of Substitutes
4.1.5.	Competitive Rivalry
4.1.6.	Futuristic Approach to Porter’s 5 Force Model (2017-2027)
4.2.	PEST Analysis
4.2.1.	Political 
4.2.2.	Economical
4.2.3.	Social 
4.2.4.	Technological 
4.3.	Investment Adoption Model
4.4.	Analyst Recommendation & Conclusion
Chapter 5.	Global Antiviral Combination Therapies Market, by Drug Combination
5.1.	Market Snapshot 
5.2.	Global Antiviral Combination Therapies Market by  Drug Combination, Performance - Potential Analysis
5.3.	Global Antiviral Combination Therapies Market Estimates & Forecasts by Drug Combination 2017-2027 (USD Billion)
5.4.	Antiviral Combination Therapies Market, Sub Segment Analysis
5.4.1.	  NRTI/NNRTI
5.4.2.	Integrase Inhibitor/NRTI
5.4.3.	NRTI
5.4.4.	NRTI/Protease Inhibitor
5.4.5.	Others 
Chapter 6.	Global Antiviral Combination Therapies Market, by Type  
6.1.	Market Snapshot 
6.2.	Global Antiviral Combination Therapies Market by Type, Performance - Potential Analysis
6.3.	Global Antiviral Combination Therapies Market Estimates & Forecasts by Type 2017 -2027 (USD Billion)
6.4.	Antiviral Combination Therapies Market, Sub Segment Analysis
6.4.1.	  Branded
6.4.2.	Generic
Chapter 7.	Global Antiviral Combination Therapies Market, by Indication   
7.1.	Market Snapshot 
7.2.	Global Antiviral Combination Therapies Market by Indication, Performance - Potential Analysis
7.3.	Global Antiviral Combination Therapies Market Estimates & Forecasts by Indication  2017 -2027 (USD Billion)
7.4.	Antiviral Combination Therapies Market, Sub Segment Analysis
7.4.1.	   HIV
7.4.2.	Hepatitis
7.4.3.	Others
Chapter 8.	Global Antiviral Combination Therapies Market, by Route of Administration  
8.1.	Market Snapshot 
8.2.	Global Antiviral Combination Therapies Market by Route of Administration, Performance - Potential Analysis
8.3.	Global Antiviral Combination Therapies Market Estimates & Forecasts by Route of Administration  2017 -2027 (USD Billion)
8.4.	Antiviral Combination Therapies Market, Sub Segment Analysis
8.4.1.	   Oral
8.4.2.	 Intravenous
Chapter 9.	Global Antiviral Combination Therapies Market, by Distribution Channel  
9.1.	Market Snapshot 
9.2.	Global Antiviral Combination Therapies Market by Distribution Channel, Performance - Potential Analysis
9.3.	Global Antiviral Combination Therapies Market Estimates & Forecasts by Distribution Channel 2017 -2027 (USD Billion)
9.4.	Antiviral Combination Therapies Market, Sub Segment Analysis
9.4.1.	 Hospital Pharmacies
9.4.2.	Retail Pharmacies
9.4.3.	Others  
Chapter 10.	Global Antiviral Combination Therapies Market, Regional Analysis
10.1.	Antiviral Combination Therapies Market, Regional Market Snapshot 
10.2.	North America Antiviral Combination Therapies Market 
10.2.1.	U.S. Antiviral Combination Therapies Market
10.2.1.1.	Drug Combination breakdown estimates & forecasts, 2017-2027
10.2.1.2.	Type breakdown estimates & forecasts, 2017-2027
10.2.1.3.	Indication breakdown estimates & forecasts, 2017-2027
10.2.1.4.	Route of Administration breakdown estimates & forecasts, 2017-2027
10.2.1.5.	Distribution Channel breakdown estimates & forecasts, 2017-2027
10.2.2.	Canada Antiviral Combination Therapies Market
10.3.	Europe Antiviral Combination Therapies Market Snapshot
10.3.1.	U.K. Antiviral Combination Therapies Market 
10.3.2.	Germany Antiviral Combination Therapies Market
10.3.3.	France Antiviral Combination Therapies Market
10.3.4.	Spain Antiviral Combination Therapies Market
10.3.5.	Italy Antiviral Combination Therapies Market
10.3.6.	Rest of Europe Antiviral Combination Therapies Market
10.4.	Asia-Pacific Antiviral Combination Therapies Market Snapshot
10.4.1.	China Antiviral Combination Therapies Market 
10.4.2.	India Antiviral Combination Therapies Market 
10.4.3.	Japan Antiviral Combination Therapies Market
10.4.4.	Australia Antiviral Combination Therapies Market
10.4.5.	South Korea Antiviral Combination Therapies Market
10.4.6.	Rest of Asia Pacific Antiviral Combination Therapies Market
10.5.	Latin America Antiviral Combination Therapies Market Snapshot
10.5.1.	Brazil Antiviral Combination Therapies Market
10.5.2.	Mexico Antiviral Combination Therapies Market
10.6.	Rest of The World Antiviral Combination Therapies Market

Chapter 11.	Competitive Intelligence
11.1.	Top Market Strategies
11.2.	Company Profiles
11.2.1.	Celltrion, Inc.
11.2.1.1.	Key Information
11.2.1.2.	Overview
11.2.1.3.	Financial (Subject to Data Availability)
11.2.1.4.	Product Summary
11.2.1.5.	Recent Developments
11.2.2.	GlaxoSmithKline plc
11.2.3.	Gilead Sciences, Inc.
11.2.4.	AbbVie, Inc.
11.2.5.	Bristol-Myers Squibb Company
11.2.6.	Janssen Global Services, LLC (Pharmaceutical Companies of Johnson & Johnson)
11.2.7.	Cipla, Inc.
11.2.8.	Mylan N.V.
11.2.9.	Merck & Co., Inc.
11.2.10.	F. Hoffmann-La Roche Ltd.
Chapter 12.	Research Process
12.1.	Research Process
12.1.1.	Data Mining
12.1.2.	Analysis
12.1.3.	Market Estimation
12.1.4.	Validation
12.1.5.	Publishing
12.2.	Research Attributes
12.3.	Research Assumption

Global Antiviral Combination Therapies Market is valued approximately USD 40.4 billion in 2019 and is anticipated to grow with a healthy growth rate of more than XX % over the forecast period 2020-2027. Antiviral Combination Therapies are drugs developed using a combination of two or more drugs for the treatment of various viral diseases including hepatitis C, HIV and hepatis B. The combination antiretroviral therapy aids in stopping the virus from multiple copies of itself in the body. Also, the triple combination of lopinavir-ritonavir and infection beta-1b holds promising potentials in the treatment of coronavirus. Researchers in healthcare organizations and companies are referring historical findings of the lopinavir-ritonavir & ribavirin combination, which was effective in lowering mortality and morbidity rate of then severe acute respiratory syndrome. Also, the key players are focusing on strategies such as product launch, innovation and merger & acquisition to sustain themselves amidst fierce competition. The growth of the market is attributed owing to the increase in investment in research and development for the development of combination medications that aid in fighting antiviral resistance, rise in prevalence of viral diseases, surge in demand for antiviral combination for the treatment of HIV would drive the growth of the market. Germany- based Boehringer Ingelheim, in April 2018, announced to invest about 75 million in a high-tech building at its Lyon Porte-des-Alpes in France to meet the growing demand for avian vaccines worldwide. Thus, with the rising prevalence of viral diseases, the need and demand for antiviral combination therapies would increase thereby, reinforcing the growth of the market during the forecast period of 2020-2027. However, stringent government regulation is hampering the growth of the market during the forecast period of 2020-2027.

The regional analysis of global Antiviral Combination Therapies market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America and Rest of the World. North America is the leading/significant region due to presence of leading players, rise in usage of antiviral combination therapies for treating viral diseases, strong pipeline of drugs, and increase in research on the development of antiviral combination drugs for treatment of COVID-19. Whereas Asia-Pacific is also anticipated to exhibit highest growth rate / CAGR over the forecast period 2020-2027.

Major market player included in this report are:
Celltrion, Inc.
GlaxoSmithKline plc
Gilead Sciences, Inc.
AbbVie, Inc.
Bristol-Myers Squibb Company
Janssen Global Services
LLC (Pharmaceutical Companies of Johnson & Johnson)
Cipla, Inc.
Mylan N.V.
Merck & Co., Inc.

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Drug Combination:
NRTI/NNRTI
Integrase Inhibitor/NRTI
NRTI
NRTI/Protease Inhibitor
Others
By Type:
Branded
Generic
By Indication:
HIV
Hepatitis
Others
By Route of Administration:
Oral
Intravenous
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year – 2017, 2018
Base year – 2019
Forecast period – 2020 to 2027

Target Audience of the Global Antiviral Combination Therapies Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors


We offer 10% free customization including country-level data, niche applications and competitive landscape with every report. This also includes a 30 minute free analyst discussion post report purchase.

Full Name*

Business Email* (Please avoid generic email IDs such as gmail, yahoo)

Phone* (Please Affix Country Code)

Need specific market information? To get a customized report, please share your exact research requirements.



Loading…